Synthesis and immunological evaluation of N-acyl modified Tn analogues as anticancer vaccine candidates

Area of Science:

• Immunology
• Glycobiology
• Vaccine Development

Background:

• Tumor-associated carbohydrate antigens (TACAs) are key targets for cancer vaccines due to their aberrant expression on tumor cells.
• Developing effective vaccines against TACAs requires strategies to elicit robust immune responses.

Purpose of the Study:

• To synthesize and evaluate N-acyl modified Tn analogues conjugated with CRM197 carrier protein as potential anticancer vaccines.
• To assess the immunogenicity and efficacy of these novel glycoconjugates in preclinical models.

Main Methods:

• Synthesis of several N-acyl modified Tn analogues.
• Conjugation of analogues with the carrier protein CRM197.
• Immunological evaluation of glycoconjugates in mice, including antibody titer determination and IFN-γ production measurement.
• Assessment of antisera reactivity with Tn-positive tumor cells.

Main Results:

• The glycoconjugate 6-CRM197 elicited higher antibody titers that cross-reacted with native Tn antigen compared to the unmodified 2-CRM197.
• Treatment with 6-CRM197 significantly increased the frequency of IFN-γ-producing lymphocytes, indicating a Th1-biased immune response.
• Antisera generated against 6-CRM197 demonstrated strong reactivity with Tn-positive tumor cells.

Conclusions:

• N-acyl modification of Tn analogues enhances their immunogenicity when conjugated to CRM197.
• The developed glycoconjugate 6-CRM197 shows significant potential as an effective anticancer vaccine candidate.
• Further investigation into this promising anticancer vaccine strategy is warranted.